Point of Care Liquid Biopsy for Cancer Treatment—Early Experience from a Community Center
Authors:
- Champica NicholasCNChampica Nicholas
- Andrea BeharryABAndrea Beharry
- Anna M. BendzsakABAnna M. Bendzsak
- Kassandra R. BissonKBKassandra R. Bisson
- Keith DadsonKDKeith Dadson
- Shaan DudaniSDShaan Dudani
- Marco IafollaMIMarco Iafolla
- Kashif IrshadKIKashif Irshad
- Kirstin PerdrizetKPKirstin Perdrizet
- William RaskinWRWilliam Raskin
- Raviya SinghRSRaviya Singh
- David Chun Cheong TsuiDTDavid Chun Cheong Tsui
Open Access
Abstract
Liquid biopsy is rapidly becoming an indispensable tool in the oncologist’s arsenal; however, this technique remains elusive in a publicly funded healthcare system, and real-world evidence is needed to demonstrate utility and feasibility. Here, we describe the first experience of an in-house point of care liquid biopsy program at a Canadian community hospital. A retrospective review of consecutive cases that underwent plasma-based next-generation sequencing (NGS) was conducted. Liquid biopsy was initiated at the discretion of clinicians. Sequencing followed a point of care workflow using the Genexus™ integrated sequencer and the Oncomine precision assay, performed by histotechnologists. Results were reported by the attending pathologist. Eligible charts were reviewed for outcomes of interest, including the intent of the liquid biopsy, results of the liquid biopsy, and turnaround time from blood draw to results available. A total of 124 cases, with confirmed or suspected cancer, underwent liquid biopsy between January 2021 and November 2023. The median turnaround time for liquid biopsy results was 3 business days (range 1–12 days). The sensitivity of liquid biopsies was 71%, compared to tissue testing in cases with matched tissue results available for comparison. Common mutations included EGFR (29%), in 86 lung cancer patients, and PIK3CA (22%), identified in 13 breast cancer patients. Healthcare providers ordered liquid biopsies to inform diagnostic investigations and treatment decisions, and to determine progression or resistance mechanisms, as these reasons often overlapped. This study demonstrates that rapid in-house liquid biopsy using point of care methodology is feasible. The technique facilitates precision treatment and offers many additional advantages for cancer care.Keywords
Funding Information
- Eli Lilly, Roche (20040020, 68023243)
- Pfizer Canada (20040020, 68023243)
- ThermoFisher (20040020, 68023243)
This publication has 28 references indexed in Scilit:
- “Plasma-first” approach for molecular genotyping in non-small cell lung cancer: A narrative reviewThe Journal of Liquid Biopsy, 2023
- Health Economic Evidence and Modeling Challenges for Liquid Biopsy Assays in Cancer Management: A Systematic Literature ReviewPharmacoEconomics, 2023
- Feasibility of Point-of-Care Genomic Profiling in the Diagnosis and Treatment of Cancer of Unknown PrimaryThe Oncologist, 2023
- ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working GroupAnnals of Oncology, 2022
- Evaluating Targeted Next-Generation Sequencing Assays and Reference Materials for NTRK Fusion DetectionThe Journal of Molecular Diagnostics, 2022
- Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive CohortJournal of Thoracic Oncology, 2021
- The need for speed in advanced non‐small cell lung cancer: A population kinetics assessmentCancer Medicine, 2021
- High concordance of actionable genomic alterations identified between circulating tumor DNA–based and tissue‐based next‐generation sequencing testing in advanced non–small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy ProgramCancer, 2021
- P89.03 Demonstrating VALUE of Liquid Biopsy for Lung Cancer in a Public Healthcare SystemJournal of Thoracic Oncology, 2021
- DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung CancerJournal of Thoracic Oncology, 2019